NCT07448727 Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT
| NCT ID | NCT07448727 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Rome Tor Vergata |
| Condition | Head & Neck Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 25 participants |
| Start Date | 2024-11-20 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 25 participants in total. It began in 2024-11-20 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate the role of early response assessment by 18F-FDG PET/CT in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma with PD-L1 CPS \>1 treated with pembrolizumab monotherapy, in accordance with routine clinical practice.
Eligibility Criteria
Inclusion Criteria: * Histological diagnosis of recurrent and/or metastatic HNSCC, not amenable for curative locoregional treatment (either surgery or radiotherapy), and amenable for first line systemic treatment * CPS PD-L1 \>=1 Exclusion Criteria: * Any controindication to immune checkpoint inhibitors
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07448727 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Head & Neck Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07448727 currently recruiting?
Yes, NCT07448727 is actively recruiting participants. Contact the research team at vincenzo.formica@uniroma2.it for enrollment information.
Where is the NCT07448727 trial being conducted?
This trial is being conducted at Rome, Italy.
Who is sponsoring the NCT07448727 clinical trial?
NCT07448727 is sponsored by University of Rome Tor Vergata. The trial plans to enroll 25 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.